These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 26048105)

  • 1. The relation between lymphocyte-monocyte ratio and renal cell carcinoma.
    Balta S; Demirer Z; Aparci M; Demirkol S; Ozturk C
    Urol Oncol; 2015 Oct; 33(10):421. PubMed ID: 26048105
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibition of lymphocyte proliferative responses by renal cell carcinoma extract.
    Malinowski K; Kono K; Takayama T; Terashima T; Tsukuda K; Waltzer W; Rapaport FT
    Transplant Proc; 1997; 29(1-2):839-41. PubMed ID: 9123549
    [No Abstract]   [Full Text] [Related]  

  • 3. [Phenotypic difference of lymphocytes circulating in tumorous renal artery and renal vein in patients with renal cell carcinoma].
    Shiraiwa H; Nishijima Y; Akaza H; Uchida K; Kawai K; Sasaki A; Hattori K; Miyanaga N; Koiso K
    Nihon Hinyokika Gakkai Zasshi; 1993 Jul; 84(7):1244-7. PubMed ID: 8355438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immunohistochemical study of renal cell carcinoma with monoclonal anti Leu-M1 antibody].
    Senga Y; Satomi Y; Fukuda M; Ebato T; Hosaka M; Tanaka Y; Misugi K
    Nihon Hinyokika Gakkai Zasshi; 1987 Jul; 78(7):1246-51. PubMed ID: 3500350
    [No Abstract]   [Full Text] [Related]  

  • 5. An assessment of lymphocytic population in peripheral blood of patients with renal cell carcinoma before and after embolization.
    Osada J; Pietruczuk M; Dabrowska M; Kordecki K; Janica J; Walecki J
    Rocz Akad Med Bialymst; 2000; 45():228-39. PubMed ID: 11712434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammatory response predicts survival in renal cancer.
    Kerr C
    Lancet Oncol; 2006 Apr; 7(4):284. PubMed ID: 16598873
    [No Abstract]   [Full Text] [Related]  

  • 7. [Therapeutic indication of interferons for renal cell carcinoma].
    Harano M; Naito S
    Nihon Rinsho; 2006 Feb; 64 Suppl 2():647-51. PubMed ID: 16523970
    [No Abstract]   [Full Text] [Related]  

  • 8. [Immunohistochemical characterization of renal cell carcinomas].
    Bohle B; Waldherr R; Schwechheimer K; Moldenhauer G; Momburg F
    Verh Dtsch Ges Pathol; 1986; 70():274-8. PubMed ID: 3825252
    [No Abstract]   [Full Text] [Related]  

  • 9. Prognostic factors for metastatic kidney cancer.
    Drucker BJ; Mazumdar M; Motzer RJ
    Cancer Treat Res; 2003; 116():139-53. PubMed ID: 14650830
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunologic studies of alveolar macrophages from patients with metastatic renal cell carcinoma.
    Thomassen MJ; Barna BP; Wiedemann HP; Bukowski RM; Farmer M; Ahmad M
    Am Rev Respir Dis; 1990 May; 141(5 Pt 1):1256-8. PubMed ID: 2339845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA class I expression in primary and metastatic renal cell carcinoma.
    Buszello H; Ackermann R
    Investig Urol (Berl); 1994; 5():55-9. PubMed ID: 7719321
    [No Abstract]   [Full Text] [Related]  

  • 12. Prognostic, clinicopathological, and immune correlation of NLRP3 promoter methylation in kidney renal clear cell carcinoma.
    Long Q; He L; Peng J; Meng Q; Zhang C; Chen M; Wang X; Zhu W; Zheng F; Dong P; Deng W
    Clin Transl Med; 2021 Oct; 11(10):e528. PubMed ID: 34709757
    [No Abstract]   [Full Text] [Related]  

  • 13. Monocyte/macrophage-directed antibodies Ki-M3 and Ki-M7 detect renal-cell carcinomas.
    Kaiser U; Hansmann ML; Papadopoulos I; Radzun HJ
    Int J Cancer Suppl; 1988; 3():45-9. PubMed ID: 3209299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating cancer cells in renal-cell carcinoma.
    Pontes JE; Pescatori E; Connelly R; Hashimura T; Tubbs R
    Prog Clin Biol Res; 1990; 348():1-12. PubMed ID: 2385602
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunohistochemical analysis of HLA class II antigens and tumor infiltrating mononuclear cells in renal cell carcinoma: correlation with clinical and histopathological data.
    Brasanac D; Marković-Lipkovski J; Hadzi-Djokić J; Müller GA; Müller CA
    Neoplasma; 1999; 46(3):173-8. PubMed ID: 10613593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New horizons in the treatment of renal cell cancer.
    Wagstaff J
    Ann Oncol; 2006 Sep; 17 Suppl 10():x19-22. PubMed ID: 17018722
    [No Abstract]   [Full Text] [Related]  

  • 17. [Expression of LeX antigens in renal adenocarcinoma differentiation and the prognosis].
    Fukushi Y; Saito S; Orikasa S; Ohtani H
    Nihon Hinyokika Gakkai Zasshi; 1988 Jun; 79(6):1090-5. PubMed ID: 2903265
    [No Abstract]   [Full Text] [Related]  

  • 18. [Renal collecting duct carcinoma associated with tumor embolus in the inferior vena cava].
    Guo LL; Wang MQ; Cai YR; Wang Y
    Zhonghua Bing Li Xue Za Zhi; 2005 Feb; 34(2):123-4. PubMed ID: 15842816
    [No Abstract]   [Full Text] [Related]  

  • 19. Combination immunotherapy in renal cell carcinoma.
    Drake CG
    Clin Adv Hematol Oncol; 2016 Feb; 14(2):99-100. PubMed ID: 27057808
    [No Abstract]   [Full Text] [Related]  

  • 20. Molecular markers in renal cell carcinoma: not quite ready for "prime time".
    Thrasher JB
    Cancer; 1999 Dec; 86(11):2195-7. PubMed ID: 10590356
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.